MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis

Nature Communications

Volumn 7, Issue , 2016, Pages

  Alivernini, Stefano ^a   Kurowska Stolarska, Mariola ^b   Tolusso, Barbara ^a   Benvenuto, Roberta ^a   Elmesmari, Aziza ^b   Canestri, Silvia ^a   Petricca, Luca ^a   Mangoni, Antonella ^a   Fedele, Anna Laura ^a   Di Mario, Clara ^a   Gigante, Maria Rita ^a   Gremese, Elisa ^a   McInnes, Iain B ^b   Ferraccioli, Gianfranco ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; B CELL ACTIVATING FACTOR; CD27 ANTIGEN; CD40 LIGAND; CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN D; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 21; INTERLEUKIN 6; MICRORNA 155; MICRORNA; MIRN155 MICRORNA, HUMAN; ONCOPROTEIN; PROTO-ONCOGENE PROTEIN SPI-1; TRANSACTIVATOR PROTEIN;

ANTIBODY; BLOOD; CELLS AND CELL COMPONENTS; DISEASE INCIDENCE; GENE EXPRESSION; PATHOGEN; PROTEIN; RNA; RODENT;

ADULT; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE ACTIVATION; BIOPSY; CHRONIC INFLAMMATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; OSTEOARTHRITIS; PHENOTYPE; RHEUMATOID ARTHRITIS; SYNOVIUM; AGED; B LYMPHOCYTE; BLOOD; CYTOLOGY; DOWN REGULATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; SECRETION (PROCESS); SYNOVIAL FLUID;

MUS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOGLOBULIN D; LYMPHOCYTE ACTIVATION; MALE; MICRORNAS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; SYNOVIAL FLUID; SYNOVIAL MEMBRANE; TRANS-ACTIVATORS; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 7;

EID: 84989308236     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12970     Document Type: Article

References (48)

1. Dennis, Jr G. et al. Synovial phenotypes in Rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res. Ther. 16, R90 (2014).
2. Klimiuk, P. A., Goronzy, J. J., Björnsson, J., Beckenbaugh, R. D. & Weyand, C. M. Tissue cytokines patterns distinguished variants of rheumatoid synovitis. Am. J. Pathol. 151, 1311-1319 (1997).
3. Humby, F. et al. Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in Rheumatoid Arthritis. Plos Med. 6, e1 (2009).
4. Musilova, K. & Mraz, M. MicroRNAs in B-cell lymphomas: how a complex biology gets more complex. Leukemia 29, 1004-1017 (2015).
5. Baxter, D., McInnes, I. B. & Kurowska-Stolarska, M. Novel regulatory mechanisms in inflammatory arthritis: a role for microRNA. Immunol. Cell. Biol. 90, 288-292 (2012).
6. Kurowska-Stolarska, M. et al. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc. Natl Acad. Sci. USA 108, 11193-11198 (2011).
7. Rodriguez, A. et al. Requirement of bic/microRNA-155 for normal immune function. Science 316, 608-611 (2007).
8. Thai, T. H. et al. Regulation of the germinal center response by microRNA-155. Science 316, 604-608 (2007).
9. Lu, D. et al. The miR-155-PU.1 axis acts on Pax5 to enable efficient terminal B cell differentiation. J. Exp. Med. 211, 2183-2198 (2014).
10. Berglund, L. J. et al. IL-21 signalling via STAT3 primes human naive B cells to respond to IL-2 to enhance their differentiation into plasmablasts. Blood 122, 3940-3950 (2013).
11. Rozovski, U. et al. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood 123, 3797-3802 (2014).
12. Poovassery, J. S. & Bishop, G. A. Type I IFN receptor and the B cell antigen receptor regulate TLR7 responses via distinct molecular mechanisms. J. Immunol. 189, 1757-1764 (2012).
13. Deenick, E. K. et al. Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells. J. Exp. Med. 210, 2739-2753 (2013).
14. Avery, D. T. et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J. Exp. Med. 18, 155-171 (2010).
15. Ferraccioli, G. et al. Biomarkers of Good EULAR response to the B cell depletion therapy in all seropositive Rheumatoid Arthritis patients: clues for the pathogenesis. PLoS ONE 7, e40362 (2012).
16. Moura, R. A. et al. BAFF and TACI gene expression are increased in patients with untreated very early rheumatoid arthritis. J. Rheumatol. 40, 1293-1302 (2013).
17. Zou, G. M., Chen, J. J., Yoder, M. C., Wu, W. & Rowley, J. D. Knockdown of Pu.1 by small interfering RNA in CD34 embryoid body cells derived from mouse ES cells turns cell fate determination to pro-B cells. Proc. Natl Acad. Sci. USA 102, 13236-13241 (2005).
18. Nutt, S. L. & Kee, B. L. The transcriptional regulation of B cell lineage commitment. Immunity 26, 715-725 (2007).
19. Boller, S. & Grosschedl, R. The regulatory network of B-cell differentiation: a focused view of early B-cell factor 1 function. Immunol. Rev. 261, 102-115 (2014).
20. Vigorito, E. et al. MicroRNA-155 regulates the generation of Immunoglobulin class-switched plasma cells. Immunity 27, 847-859 (2007).
21. White, C. A. et al. Histone deacetylase inhibitors upregulate B cell microRNAs that silence AID and Blimp-1 expression for epigenetic modulation of antibody and autoantibody responses. J. Immunol. 193, 5933-5950 (2014).
22. Shen, T., Sanchez, H. N., Zan, H. & Casali, P. Genome-wide analysis reveals selective modulation of microRNAs and mRNAs by histone deacetylase inhibitor in B cells induced to undergo class-switch DNA recombination and plasma cell differentiation. Front. Immunol. 6, 627 (2015).
23. van de Stadt, L. A. et al. Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis Rheumatol. 63, 3226-3233 (2011).
24. Porter, D. et al. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an openlabel, randomised controlled, non-inferiority, trial. Lancet 388, 239-247 (2016).
25. Klein, U. & Dalla-Favera, R. Germinal centres: role in B-cell physiology and malignancy. Nat. Rev. Immunol. 8, 22-33 (2008).
26. Canete, J. D. et al. Clinical significance of synovial lymphoid neogenesis and its reversal after-tumor necrosis factor alpha therapy in rheumatoid arthritis. Ann. Rheum. Dis. 68, 751-756 (2009).
27. Canete, J. D. & Pablos, J. L. Lymphoid aggregation is not lymphoid neogenesis: comment on the article by Klaasen et al. Arthritis Rheum. 62, 2825-2826 (2010).
28. van de Sande, M. G. et al. Presence of lymphocyte aggregates in the synovium of patients with early arthritis in relationship to diagnosis and outcome: is it a constant feature over time? Ann. Rheum. Dis. 70, 700-703 (2011).
29. Cantaert, T. et al. B lymphocyte autoimmunity in rheumatoid synovitis is independent of ectopic lymphoid neogenesis. J. Immunol. 181, 785-794 (2008).
30. Lindenau, S. et al. Aberrant activation of B cells in patients with rheumatoid arthritis. Ann. NY Acad. Sci. 987, 246-248 (2003).
31. Odendahl, M. et al. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 4, 1614-1621 (2005).
32. Dorsett, Y. et al. MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc Igh translocation. Immunity 28, 630-638 (2008).
33. Teng, G. et al. MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. Immunity 28, 621-629 (2008).
34. Rai, D., Karanti, S., Jung, I., Dahia, P. L. & Aguiar, R. C. Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma. Cancer Genet. Cytogenet. 181, 8-15 (2008).
35. Rodríguez-Bayona, B., Ramos-Amaya, A., Pérez-Venegas, J. J., Rodríguez, C. & Brieva, J. A. Decreased frequency and activated phenotype of blood CD27 IgD IgM B lymphocytes is a permanent abnormality in systemic lupus erythematosus patients. Arthritis. Res. Ther. 12, R108 (2010).
36. Mahmood, Z. et al. CD27-IgD- memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis. Arthritis. Res. Ther. 17, 61 (2015).
37. Tangye, S. H. & Tanlington, D. M. Memory B cells: effectors of long-lived immune responses. Eur. J. Immunol. 39, 2065-2075 (2008).
38. Doorenspleet, M. E. et al. Rheumatoid arthritis synovial tissue harbours dominant B-cell and plasma-cell clones associated with autoreactivity. Ann. Rheum. Dis. 73, 756-762 (2014).
39. Sallusto, G., Geginat, J. & Lanzavecchia, A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Imm 22, 745-763 (2004).
40. Singh, H., Pongubala, J. M. & Medina, K. L. Gene regulatory networks that orchestrate the development of B lymphocyte precursors. Adv. Exp. Med. Biol. 596, 57-62 (2007).
41. Smigielska-Czepiel, K. et al. Comprehensive analysis of miRNA expression in T-cell subsets of rheumatoid arthritis patients reveals defined signatures of naive and memory Tregs. Genes Immun. 15, 115-125 (2014).
42. Aletaha, D. et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol. 62, 2569-2581 (2010).
43. Taylor, W. et al. Classification criteria for psoriatic arthritis. Development of new criteria from a large international study. Arthritis Rheumatol. 54, 2665-2673 (2006).
44. van de Sande, M. G. et al. Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardization to be used in clinical trials. Ann. Rheum. Dis. 70, 423-427 (2011).
45. Bancroft, J. D. & Stevens, A. in Theory and practice of histological techniques 4th edn (Churchill Livingstone, 1996).
46. Manzo, A. et al. Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur. J. Immunol. 35, 1347-1359 (2005).
47. Sanz, I., Wei, C., Lee, F. E. & Anolik, J. Phenotypic and functional heterogeneity of human memory B cells. Semin. Immunol. 20, 67-82 (2008).
48. Kerkman, P. F. et al. Circulating plasmablasts/plasmacells as a source of anticitrullinated protein antibodies in patients with rheumatoid arthritis. Ann. Rheum. Dis. 72, 1259-1263 (2016).